
Dr. O'Neill serves as a member of the Executive Board and provides consulting on many aspects of vision science with a specific focus on drug development and nonclinical considerations for regulatory submissions. Dr. O’Neill has 30 years of biotechnology and pharmaceutical development experience. Currently, he is a Co-Founder, Chief Executive Officer and Board Chair at MCAL Therapeutics, Inc. that is developing a novel evaporative dry eye therapy. From 2004 to 2023 Dr. O’Neill was Vice President of nonclinical development at BioMarin Pharmaceutical Inc., During that tenure there were 10 marketed approvals across multiple molecular platforms and indications. From 1995 to 2004, Dr. O’Neill progressed in both scientific and management roles at Genentech, Inc. Among other efforts, Dr. O'Neill led nonclinical development efforts regarding anti-angiogenic molecules including the targeted oncology monoclonal antibody AvastinTM, and the intra-vitreally delivered monoclonal antibody fragment LucentisTM, a treatment for the neovascular form of age-related macular degeneration. Dr. O’Neill is a Co-Founder of SARcode BioSciences, Inc. that developed the inflammatory dry eye treatment XiidraTM. SARcode was acquired in 2014 by Shire Pharmaceutical Inc. XiidraTM is currently marketed by Bausch+Lomb. Dr. O'Neill is an Adjunct Professor in the Pharmacology and Toxicology Graduate Group at University of California, Davis. He has contributed to over 70 regulatory submissions worldwide and has coauthored over 80 peer-reviewed publications. Dr. O’Neill has been a Diplomate of the American Board of Toxicology since 1995.